by Non-small cell lung cancer is the most common type of lung cancer which affects the tissues of the lungs. Personalized protein therapeutics aim to treat non-small cell lung cancer through targeted drug delivery while minimizing potential side-effects. These therapeutics involve engineering proteins and peptides which can bind to specific cancer cell receptors to deliver anti-cancer drugs or directly interfere with cancer growth. This targeted approach is advantageous over conventional chemotherapy as it provides greater efficacy with reduced toxicity.
The global Non-Small Cell Lung Cancer Market is estimated to be valued at US$ 27252.31 Mn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Advancements in targeted drug delivery and personalized medicine continue to shape the non-small cell lung cancer treatment landscape. One of the key ongoing trends is the development of novel antibody-drug conjugates which combine monoclonal antibodies with cytotoxic agents specifically designed for lung cancer. These next-generation conjugates have demonstrated improved tumor targeting ability with tailored drug release profiles. Nanotechnology has also allowed encapsulation of anti-cancer agents into nanoparticles for prolonged systemic circulation and enhanced permeability into tumors. Ongoing research in protein engineering and immunotherapies is further expected to bring personalized protein therapeutics closer to clinical application.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as significant capital investment is required for R&D and clinical trials to introduce new drugs. However, biologics have increased the threat level.
Bargaining power of buyers: The bargaining power of buyers is moderate as the introduction of new targeted therapies and immunotherapies have increased treatment options. However, the life-threatening nature of cancer increases dependence on available drugs.
Bargaining power of suppliers: The bargaining power of suppliers is high given the concentration of prominent pharmaceutical companies developing innovative oncology drugs and biologics. Suppliers can influence prices due to patented or unique products facing less threat of substitution.
Threat of new substitutes: The threat of new substitutes is high as researchers continuously work to develop novel targeted therapies and combinations with lower side effects. Immunotherapies are transforming the treatment landscape at a greater pace.
Competitive rivalry: The competitive rivalry is high characterized by frequent new product launches, increasing investments in immunotherapy and personalized medicine research clubs. Players compete based on innovative product features and clinical evidence.
Key Takeaways
The Global Non-Small Cell Lung Cancer Market Size is expected to witness high growth over the forecast period.
Regionally, North America dominates currently due to higher diagnosis rates and rapid adoption of premium therapies. However, Asia Pacific is anticipated to record fastest gains supported by improving access to care across middle-income countries and increasing incidence associated with smoking trends and pollution.
Key players operating in the Non-Small Cell Lung Cancer market are AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
